This edition presents key opinion leader (KOL) views on recent developments in the targeted asthma treatment market
Topics covered include; GlaxoSmithKline’s (GSK) presentation of new data at the American Academy of Allergy, Asthma & Immunology Annual Meeting (AAAAI 2017) which demonstrates that efficacy of mepolizumab (Nucala) is not affected by the presence of nasal polyps (which can be indicative of a recalcitrant asthma phenotype), and new data for mepolizumab from the Phase III MUSCA trial is also discussed.
Teva’s presentation at AAAAI 2017 of new data showing that patients with inadequately controlled asthma and aspirin sensitivity received significant clinical improvement in asthmatic symptoms with reslizumab (Cinqiar/Cinqaeor) therapy. Roche/Genentech’s publication of ‘real world’ data from the PROSPERO study involving omalizumab (Xolair), with outcomes reflecting reductions in exacerbation frequency and hospitalisations achieved in earlier controlled clinical trials.
Business Questions: - In March 2017, GSK presented new data at AAAAI 2017 which demonstrates that mepolizumab’s efficacy is not affected by the presence of nasal polyps, but what is the significance of this data and what impact will it have on prescribing practice? - At AAAAI 2017, Teva presented data showing that patients with inadequately controlled asthma and aspirin sensitivity received significant improvement in symptoms with reslizumab therapy, but what is the prevalence of aspirin sensitivity and how will the data influence prescribing practice? - GSK and Teva have both published results from meta-analysis of Phase III studies that prove efficacy of mepolizumab and reslizumab respectively in a subgroup of patients acknowledged to be recalcitrant to standard therapies, but which of these products will be most appealing to prescribers and patients? - In March 2017, GSK published new data from the Phase III MUSCA study demonstrating mepolizumab’s efficacy in the treatment of severe asthma with an eosinophilic phenotype; primary outcomes, for the first time, included patient reported quality of life improvements. What is the impact of this data and can mepolizumab usage be expected to increase? - Roche/Genentech published new data from the PROSPERO study that confirms omalizumab’s efficacy in treating allergic asthma in a ‘real world’ setting. How is this data likely to be received amongst prescribers and will omalizumab usage increase?
Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.
Our reports have been used by over 10K customers, including:
195 pages •
By BioInformant Worldwide, L.L.C.
• Sep 2018
EXECUTIVE SUMMARY CAR-T cell therapy is a remarkably promising treatment for cancer patients. This emerging treatment is the biggest breakthrough since the introduction of chemotherapy. Already two products (Kymriah and Yescarta) have been approved by the U.S. FDA and European EMA for different cancer indications. What...
The Global Cancer Monoclonal Antibody Partnering 2012-2018: Deal trends, players, financials and forecasts report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in cancer monoclonal antibody partnering...
The global hydrophobic interaction chromatography market is projected to grow at a CAGR of 7.5%. The global hydrophobic interaction chromatography market is projected to reach USD 418.2 million in 2023 from USD 291.3 million in 2018, at a CAGR of 7.5%. Increasing demand for monoclonal antibodies and R&D expenditure in the biopharmaceutical...
420 pages •
By Roots Analysis Private Ltd.
• Aug 2018
INTRODUCTION Given the increasing focus on personalized medicine, biologics have established a strong foothold in the pharmaceutical industry. Owing to several beneficial features, such as high specificity, and a favorable safety profile, antibody based pharmacological interventions presently represent the largest class...
220 pages •
By The Business Research Company
• Jul 2018
Biologics Global Market Opportunities And Strategies By Product Type: Monoclonal Antibodies (mAbs), Therapeutic Proteins and Vaccines; By Region, By Country, With Forecast Until 2021 The biologics industry comprises companies manufacturing biological products that are derived from genetically modified proteins and human...